# Prevalence and factors associated with tobacco use among patients with tobacco related illness in four national referral hospitals of Kenya

Valerian Mwenda<sup>1</sup>, Lazarus Odeny<sup>3</sup>, Shukri Mohamed<sup>10</sup>, Gladwell Gathecha<sup>1</sup>, Anne Kendagor<sup>1</sup>, Dorcas Kiptui<sup>1</sup>, Florence Jaguga<sup>4</sup>, Beatrice Mugi<sup>5</sup>, Caroline Mithi<sup>6</sup>, Kennedy Okinda<sup>7</sup>, Daniel Mwai<sup>8</sup>, David Njuguna<sup>2</sup>, Winnie Awuor<sup>9</sup>, Rachel Kitonyo-Devotsu<sup>9</sup>, Jane Rahedi Ong'ang'o<sup>3</sup>

- 1. Department of Non-communicable Diseases, Ministry of Health, Nairobi, Kenya
- 2. Department of Planning and Health Financing, Ministry of Health, Nairobi, Kenya
- 3. Kenya Medical Research Institute, Nairobi, Kenya
- 4. Moi Teaching and Referral Hospital, Eldoret, Kenya
- 5. Kenyatta National Hospital, Nairobi, Kenya
- 6. Kenyatta University Teaching, Referral and Research Hospital, Nairobi, Kenya
- 7. Kenyatta National Hospital-Othaya Referral Hospital, Othaya, Kenya
- 8. University of Nairobi, Nairobi, Kenya
- 9. Development Gateway, Nairobi, Kenya
- 10. African Population and Health Research Center, Nairobi, Kenya

## Abstract

## Background

Tobacco use is a risk factor for many chronic health conditions. Demonstrating the link between tobacco use and disease burden can strengthen tobacco control. We estimated the prevalence and correlates of tobacco use among patients with tobacco related illnesses (TRI) at four national referral hospitals in Kenya.

#### Methods

We conducted a cross-sectional study among patients with four TRI (cancer, cardiovascular diseases, cerebrovascular disease and pulmonary tuberculosis) during January–October 2022. Cases were identified from medical records and a questionnaire used to collect socio-demographic information and tobacco use history. Descriptive statistics were used to estimate prevalence of tobacco use. Multiple logistic regression models were used to identify factors associated tobacco use among patients with TRI.

## Results

We identified 2032 individuals with TRI; 46% (939/2,032) had age  $\geq 60$  years, and 61% (1,241/2,032) were male. About 45% (923/2,032) were ever tobacco users (6% percent current and 39% former tobacco users). Comorbidities were present in 28% of the participants. Most (92%) of the patients had been diagnosed with the TRI within the previous five years. The most frequent TRI were oral pharyngeal cancer (36% [725/2,032]), nasopharyngeal cancer (12% [246/2.032]) and lung cancer (10% [202/2,032]). Patients >60 years (aOR 2.24, 95% CI: 1.84, 2.73) and not in a marital union (aOR 1.21, 95% CI: 1.03, 1.42) had higher odds of tobacco use. Female patients (aOR 0.35, 95% CI: 0.30, 0.41) and those with no history of alcohol use (aOR

0.27, 95% CI: 0.23, 0.31), had less odds of tobacco use. Odds of tobacco use increased with age and decreased with increasing education level.

## Conclusion

Prevalence of tobacco use was high among patients with TRI in Kenya, especially among older, male, less educated, unmarried, and alcohol users. We recommend sustained tobacco use screening and cessation programs among patients with TRI as part of clinical care.

Key words: tobacco use; tobacco-related illnesses; prevalence; Kenya

## Background

Tobacco use is a recognized risk factor for many chronic health conditions [1,2]. Health conditions with an established link to tobacco use include cancers [3–6], cardiovascular diseases [7–12], chronic obstructive pulmonary disease (COPD) [13–15], tuberculosis [16–25] and pneumonia [26,27]. Tobacco smoking is associated with a known 70% increase in risk of adverse health consequences and is also considered as a main risk factor leading to death globally [28]. Diseases related to tobacco use were ranked 2<sup>nd</sup> highest among all diseases burdening people globally in 2015 [3]. Overall, 7.69 million deaths and 200 million disability-adjusted life years (DALYS) were linked to smoking tobacco use in 2019 globally [29]. This accounted for 13.6% of all deaths and 7.9% of all DALYS for that year. Specifically, tobacco use has been linked to 24% and 44% of DALYs caused by Ischemic heart disease (IHD) and chronic obstructive pulmonary disease (COPD), respectively [30–32].

Current smoking contributed to the largest proportion of deaths out of the 87 risk factors included in the Global Burden of Disease study 2019 [33]. In the same year (2019), the Years of Life Lost (YLL) exceeded the Years Lived with Disability (YLDS) due to smoking tobacco use, with 168 million YLL compared to 31.6 million YLD. A higher Social Demographic Index (SDI) level has been associated with a decrease in the YLL to YLD Ratio. The lower the ratio, the greater the proportion of individuals living with chronic health illnesses due to tobacco smoking. Ischaemic heart disease, COPD, tracheal, bronchus and lung cancer, and stroke together accounted for approximately 72 % of all deaths attributable to smoking tobacco use in both sexes out of the 36 health outcomes related to tobacco use [32].

The World Health Organisation (WHO) currently estimates that 8 million people are dying each year from tobacco use and a majority (80%) of them are from low- and middle-income countries

[34]. Unless countries take strict tobacco control measures, the annual burden of tobacco is expected to rise to 8 million deaths a year by 2030, accounting for 10% of all deaths expected that year. Unfortunately, despite the documented risk of disease or death from tobacco related illnesses, the global burden of tobacco use remains very high. The number of current smokers globally is estimated at 1.3 billion [35]. The Kenya non-communicable disease STEPs survey of 2015 reported the country prevalence of tobacco use as 13.3% with a male use of 23% and female prevalence of 4% [36].

Even though tobacco consumption is a significant risk factor for both communicable and noncommunicable diseases, there is limited data on tobacco use habits among individuals suffering from these illnesses in Kenya. Such data would be valuable to guide both policy and clinical teams in tobacco cessation programs. Furthermore, the findings on cost of health care for tobacco-related illnesses will help to inform stronger policy interventions that are required to minimize tobacco use and the resulting disease burden in Kenya. Therefore, we sought to assess the prevalence of tobacco use among patients with at least one of four major TRI, at the four national referral hospitals in Kenya.

## Methods

## Study design and study sites

This was a cross-sectional study conducted at the four national referral hospitals of Kenya namely Kenyatta National Hospital (KNH), Moi Teaching and Referral Hospital (MTRH), Kenyatta National Hospital-Othaya Referral Hospital (KNH-ORH), and Kenyatta University Teaching, Referral and Research Hospital (KUTRRH). These referral hospitals provide outpatient and in-patient services to a wide population country-wide and attend to patients with the four study conditions (Cancer, CVD, COPD, and pulmonary tuberculosis).

## **Study Population**

These were patients with tobacco related illnesses (TRIs) receiving treatment as out-patients or in-patients at the four national referral hospitals. The TRIs included cancers (oral-pharyngeal, laryngeal, lung, nasopharyngeal, oesophageal), CVDs (myocardial infarction, stroke, peripheral arterial diseases), COPD (chronic bronchitis, emphysema) and pulmonary tuberculosis (PTB).

Patients were eligible for the study if they were 18 years and above, had at least one of the selected tobacco related illnesses, and had presented to the hospital for treatment. Non-consenting patients and those with severe incapacitation were considered not eligible to participate in the study.

## Sample size determination and sampling

The sample size was computed using the finite population sample size calculation formula and assuming a prevalence of tobacco use of 13% among patients with tobacco-related illnesses admitted to hospitals [37] and a non-response rate of 85%. We made an adjustment for age groups that were considered likely to have onset of cigarette smoking attributable illnesses (4 categories: 35-54, 55-64, 65-74, and 75+ [1], number of study facilities (4 facilities) and gender (2 categories). The total sample size calculated was 1845. The sample size per facility was proportionately distributed according to their workload based on bed capacity. The study factored in the annual workload by disease category and facility for the year 2020 to assign sample size by diseases condition in each facility (Table 1)

Annual	Annual (2020) workload by disease condition (% workload)					Sample size allocation				
	Cancers		COPD	673	Comment	CV	COP	TD	T-4-1	
Facility		CVD	COPD	(6%)	Cancers	D	D	TB	Total	
KNH	8,100 (78%)	1,144	459 (4%)	325	678	96	38	56	868	
KΝΠ	8,100 (7870)	(11%)	439 (470)	(7%)	078					
MTRH	3,790 (82%)	203 (4%)	299 (6%)	0 (7%)	406	22	32	35	494	
KUTRRH	0 (82%)	0 (4%)	0 (6%)	23 (2%)	258	14	20	22	314	
KNH-	150 (120/)	(00) $(170/)$	494	1,021	20	00	((	2	1(0	
ORH	150 (12%)	600 (47%)	(39%)	(6%)	20	80	66	3	169	
Total	12,040	1,947	1,252	673	1,366	221	142	116	1 9 1 5	
Total	(74%)	(12%)	(8%)	(6%)	1,300	221	142	116	1,845	

Table 1: Distribution of sample size by hospital and disease condition

Apportioning of sample size by out-patient (OP) and in-patient (IP) was based on the ratio of annual OP workload against IP workload for each hospital. This ratio was applied on each of the condition sample sizes, except for tuberculosis that is usually managed as out-patient (Table 1).

## Sampling Procedure

This study used purposive sampling as it targeted patients with TRI. Patient records, i.e., either outpatient and inpatient files or registers, were first checked to select patients with TRI. The inpatient and outpatient registers were reviewed daily in all the relevant specialty clinics (e.g., oncology and TB clinics), surgery and medical wards during the study period to identify patients who met the inclusion criteria.

#### Variables

The history of tobacco use (smoking or smokeless tobacco) among patients with tobacco-related illnesses was the primary outcome variable. The status of tobacco use was reported as: never user, current user (daily user or less than daily user) and former user. Age of taking up tobacco

use, and duration of its use was reported. Questions for tobacco use were adapted from the STEPs survey data collection tool [38]. Individual variables included the study TRIs that all eligible patients were enrolled with. In situations that a patient had multiple TRIs the first TRI to be diagnosed was the primary diagnosis and the other conditions were recorded as co-morbidities. Any other co-morbidity reported by the patients was also established. Socio-demographic variables include age, gender, residence (urban/rural), employment status, level of education, marital status. The respondents also reported on the history of past or current alcohol consumption, defined as intake of any alcoholic beverage, of whichever type and any amount.

Diagnosis of the target conditions was based on documented clinical and diagnostic confirmatory information (bacteriology for PTB; histology for cancer and imaging for CVD). However, for COPD, only clinical presentation information was used since lung function tests records were not available.

The definition of tobacco use status applied to both tobacco smoking and the use of smokeless tobacco. Current tobacco users were individuals who were currently using a tobacco product; a current daily tobacco user was an individual who was currently using a tobacco product daily. In this instance daily meant using a tobacco product at least every day over a period of a month or more. A current less than daily tobacco user was an individual who was not a daily user, could be an occasional tobacco user (irregular frequency or rare use) and former tobacco users were individuals who were ever tobacco users and currently were not using any tobacco product.

Exposure to secondhand smoke at home was defined as individuals who reported that smoking occurs inside their homes, while exposure to secondhand smoke at work were individuals who indicated that they had been exposed to tobacco smoke at work in the past 30 days.

## Study Procedures

Nurses working at the data collection sites at the participating hospitals were identified to work as study research assistants. They were trained on the standardized data collection tool, study protocol and procedures. After the training, piloting of the study procedures was conducted.

Study subjects were interviewed by research assistants using a pretested questionnaire on tobacco use. Data was collected at the patient's bedside in the wards, while outpatient study participants were interviewed at the different clinics where they were located. The research assistants were consistently supervised by a research coordinator whose work was to spot check at least 5% randomly selected interviews conducted by the interviewers, looking for inconsistencies, incomplete details, and contradictory answers. If necessary, the research assistants were asked to return to the patient to clarify the information.

Before initiating the data collection, the respective hospital management teams and departments were introduced to the research by the study investigators. A visit was made to the health facility study sites to assess feasibility of conducting the study. The team sought cooperation from the hospital authorities to support implementation.

#### Data Management

Data collection was conducted using Kobo Toolbox (Harvard Humanitarian Initiative), which is an open-source software for collecting survey data. This allowed collection of data offline and uploading online to transmit the data to the central database. The study data IT specialist designed the databases, ensuring integrity and security of stored data through password protection and export of data for analysis. Each study participant had a unique study identifier against their records. Only key study team members had access to these data files.

# Data Analysis

Statistical Application Software (SAS version 9.0, SAS Institute Inc, CA, USA) was used to compute and analyse the study responses. Categorical characteristics were summarized as frequencies and percentages, with comparison by smoking status (current smokers, former smokers, and never smokers) and disease condition with covariates using chi-square tests. Continuous variables were summarized using means, median, standard deviations, and interquartile ranges (IQR) and tested for differences by smoking status and disease condition using Kruskal-Wallis tests. The study determined the proportion of tobacco users by disease conditions. Socio-demographic variables and tobacco product use were analyzed by disease conditions. We used bivariate and multivariate logistic regression models to assess factors that are associated with tobacco use status among patients with TRI. A 95% confidence interval was applied for all analyses. Any associations were deemed significant at 0.05 or less level of significance.

#### Ethical considerations

The study research protocol was reviewed and approved by the Kenyatta National Hospital-University of Nairobi ethics and research committee and Moi University/ Moi Teaching and Referral Hospital Institutional Research and Ethics Committee. The approval references were KNH-ERC/A/346 and FAN: 0003954 respectively. Written informed consent was obtained from each eligible participant before enrolment into the study and after thorough explanation of the risks and benefits of participating in the study.

## Results

### Characteristics of the study participants

During the study period, we collected data from 2032 individuals from the four referral hospitals. Table 2 presents the socio-demographic, behavioral and clinical factors. Majority of the patients were aged 60+ years (46%), men (61%), had primary-level education (41%), employed (54%), married (73%). Majority of the study participants were from the Kenyatta National referral hospital (53%), had never used tobacco (54%) and were consumers of alcohol (56%). Six percent of the study participants were current tobacco users, while 40% were former users. Majority of current tobacco users (88%) were male. Comorbidities were present in 28% of the study participants, with more males having comorbidities compared to females (54%). All comorbid conditions were more prevalent among males, except HIV. Most of the patients were from the outpatient departments of the hospitals (66%).

Most (92%) of the patients were diagnosed with a tobacco-related illness in the previous five years. The three most common tobacco related illnesses were oral pharyngeal cancer (36%), nasopharyngeal cancer (12%) and lung cancer (10%). Peripheral arterial disease (PAD) was the least common TRI (2%).

Variable	Category	a. Ma		b. Femal		Total
Age Categories	18-39 Years	189	54 %	162	46 %	351
Age Oulegenes		100	63	102	37	001
	40-60 Years	471	%	271	%	742
		E01	62	250	38	020
	60+ Years	581	<u>%</u> 39	358	<u>%</u> 61	939
Highest level of Education	a. No formal education	83	%	129	%	212
0			59		41	
	b. Primary	495	%	345	%	840
	c. Secondary	429	68 %	198	32 %	627
	o. cocontairy	120	66	100	34	027
	d. Post Secondary	227	%	116	%	343
	(block)	7	70 %	3	30 %	10
	(blank)	1	50	3	50	10
Employment status	a. Unemployed	464	%	460	%	924
			70		30	
	b. Employed	771	%	330	% 14	1101
	(blank)	6	86 %	1	14 %	7
			70	· ·	30	
Marital Status	a. In Union	1035	%	453	%	1488
	h Notin Union	205	38	226	62	541
	b. Not in Union	205	% 33	336	% 67	541
	(blank)	1	%	2	%	3
<b>_</b>			60		40	
Facility	KNH	646	% 59	425	% 41	1071
	KUT	135	39 %	95	41	230
			62		38	
	MTR	326	%	204	%	530
	ORH	134	67 %	67	33 %	201
		134	88	07	12	201
Tobacco Use	a. Current Tobacco User	105	%	14	%	119
		700	88	00	12	004
	b. Former Tobacco User	706	% 39	98	% 61	804
	c. Never Tobacco User	428	%	678	%	1106
			67		33	
	(blank)	2	%	1	%	3
Tobacco Smoke	a. Current Smoker	91	93 %	7	7%	98
			91	1	1 /0	50
	b. Former Smoker	680	%	64	9%	744
		105	39	710	61	1400
	c. Never Smoker	465	% 71	718	% 29	1183
	(blank)	5	%	2	29 %	7
Smokeless Tobacco Use	a. Current Smokeless user	17	71	7	29	24

# Table 2: Socio-demographic characteristics of the study participants

			%		%	
	b. Former Smokeless user	84	65 %	46	35 %	130
	c. Never Smokeless user	1135	61 % 56	734	39 % 44	1869
	(blank)	5	%	4	%	9
Alcohol use	a. Yes	944	83 % 33	191	17 % 67	1135
	b. No	294	33 % 30	593	% 70	887
	(blank)	3	%	7	%	10
Comorbidities	a. Yes	309	54 % 64	263	46 % 36	572
	b. No	929	% 60	526	% 40	1455
	(blank)	3	%	2	%	5
Hypertension	a. Yes	203	53 % 56	180	47 % 44	383
	b. No	106	% 64	83	% 36	189
	(blank)	932	%	528	%	1460
Diabetes	a. Yes	66	56 % 53	51	44 % 47	117
	b. No	243	% 64	212	% 36	455
	(blank)	932	%	528	%	1460
HIV	a. Yes	22	38 % 56	36	62 % 44	58
	b. No	287	% 64	227	% 36	514
	(blank)	932	%	528	%	1460
Heart failure	a. Yes	12	52 % 54	11	48 % 46	23
	b. No	297	% 64	252	% 36	549
	(blank)	932	%	528	%	1460
Cancer	a. Yes	7	35 % 55	13	65 % 45	20
	b. No	302	% 64	250	% 36	552
	(blank)	932	%	528	%	1460
Other Comorbidities	a. Yes	75	56 % 53	59	44 % 47	134
	b. No	234	% 64	204	% 36	438
	(blank)	932	%	528	%	1460
Patient admission status	a. Out-patient	807	60	536	40	1343

			%		%	
			63		37	
	b. In-patient	434	%	255	%	689
			62		38	
Time since diagnosis of TRI	a. < 5 years	1156	% 53	711	% 47	1867
	b. 5-10 years	50	% 50	45	% 50	95
	c. > 10 years	35	50 %	35	50 %	70
			57		43	
TRI	01. Myocardial Infarction 02. Cerebral Vascular	31	% 45	23	% 55	54
	Accident	74	% 64	91	% 36	165
	03. Peripheral arterial diseas	23	% 63	13	% 37	36
	04a. Oral-pharyngeal cancer	459	65	266	37 % 35	725
	04b. Oesophagus cancer	34	% 81	18	33 % 19	52
	05. Laryngeal cancer	144	%	34	%	178
	06. Lung cancer	107	53 %	95	47 %	202
	07. Chronic bronchitis	73	51 %	69	49 %	142
	08. Emphysema	46	56 %	36	44 %	82
	09. Tuberculosis	100	67 %	50	33 %	150
	10. Nasopharyngeal cancer	150	61 %	96	39 %	246

## Tobacco use characteristics in the study population

Among the TRI patients, the prevalence of having ever used tobacco was 45% (Table 3). The prevalence of tobacco use was highest among patients with laryngeal cancer (61%), chronic bronchitis (60%), emphysema (54%) and peripheral arterial disease (53%). Patients with CVA had the lowest prevalence of tobacco use, at 23%.

		<b>Tobacco use status</b>				
Tobacco related illnesses	Ν	Ever-used tobacco (n, %)	Never used tobacco (n, %)			
Myocardial Infarction	54	18, (33.3%)	36, (66.6%)			
Cerebral Vascular Accident	165	38, (23.0%)	127, (77.0%)			
Peripheral arterial diseases	36	19, (52.8%)	17, (47.2%)			
Oral-pharyngeal cancer	725	357, (49.2%)	368, (50.6%)			
Oesophagus cancer	52	22, (42.3%)	30, (57.7%)			
Laryngeal cancer	178	108, (60.7%)	70, (39.3%)			
Lung cancer	202	88, (43.6%)	114, (56.4%)			
Chronic bronchitis	142	85, (59.9%)	57, (40.1%)			
Emphysema	82	44, (53.7%)	38, (46.3%)			
Tuberculosis	150	51, (34.0%)	99, (66.0%)			
Nasopharyngeal cancer	246	93, (37.8%)	153, (62.2%)			
Total	2032	923, (45.4%)	1109, (54.6%)			

Table 3: Tobacco use status among patients with tobacco related illnesses, Kenya, 2022

#### Factors associated with ever tobacco use among patients with tobacco-related illnesses

Table 4 shows the association between tobacco use and various socio-demographic and health variables in the study population. For females, the odds of being tobacco users was 65% lower than that for males (aOR 0.35, 95% CI; 0.30, 0.41). An increasing positive and significant association of being a tobacco user was observed with increasing age. The odds of tobacco use were twice as high for TRI patients above 60 years compared to study those aged less than 40 years (aOR 2.24, 95% CI; 1.84, 2.73). Overall, a decreasing significant association of being a tobacco user was observed with increasing level of education. Patients with post-secondary education had 51% less odds of being tobacco users compared with those with no formal education (aOR 0.49, 95% CI; 0.37, 0.64). Patients not in marital union had 21% higher odds of

being tobacco users compared with those in some form of union (aOR 1.21; 95% CI; 1.03, 1.42). Patients with no history of alcohol use had 73% less odds of being tobacco users (aOR 0.27, 95% CI; 0.23, 0.31). Patients with time since diagnosis with TRI of more than 10 years had 53% lower odds of tobacco use compared with those with less than 5 years (aOR 0.43, 95% CI; 0.21, 0.85).

 Table 4: Factors associated with tobacco use among patients with tobacco related illnesses, Kenya, 2022

Characteristi c	Category	N, (%)	Crude OR	p- value	95%CI(OR)	Adjusted OR	p- value	95%CI(OR)
Sex	Male	811, (66%)	1			1		
	Female	112, (14%)	0.087	0.000	(0.07, 0.11)	0.351	0.000	(0.30, 0.41)
Age Categories	18-39 Years	67, (19%)	1			1		
-	40-60 Years	330, (45%)	3.372	0.000	(2.49, 4.57)	1.307	0.005	(1.08, 1.58)
	60+ Years	526, (56%)	5.361	0.000	(3.99, 7.21)	2.240	0.000	(1.84, 2.73)
Highest level of Education	No formal education	108, (51%)	1			1		
	Primary	409, (49%)	0.927	0.620 8	(0.69, 1.25)	1.189	0.090	(0.97, 1.45)
	Secondary	277, (44%)	0.769	0.098 6	(0.56, 1.05)	0.783	0.026	(0.63, 0.97)
	Post- Secondary	125, (37%)	0.555	0.000	(0.39, 0.79)	0.488	0.000	(0.37, 0.64)
Employment status	Unemploye d	379, (41%)	1			1		
	Employed	538, (49%)	1.366	0.000 5	(1.14, 1.63)	0.972	0.684	(0.85, 1.11)
Marital Status	In Union	749, (51%)	1			1		
	Not in Union	172, (32%)	0.459	0.000	(0.37, 0.57)	1.207	0.021	(1.03, 1.42)
Alcohol use	Yes	820, (73%)	1			1		
	No	102, (12%)	0.050	0.000	(0.04, 0.06)	0.270	0.000	(0.23, 0.31)

				0				
Comorbiditie s	Yes	247, (43%)	1			1		
	No	672, (46%)	0.933	0.000	(1.38, 0.21)	1.113	0.134	(0.97, 1.28)
Patient admission	Out-patient	589, (44%)	1			1		
status	In-patient	334, (49%)	1.214	0.040	(1.01, 1.46)	1.051	0.455	(0.92, 1.20)
Time since diagnosis of	< 5 years	865, (47%)	1			1		
TRĬ	5-10 years	35, (37%)	0.669	0.064 8	(0.44, 1.03)	0.656	0.161	(0.36, 1.18)
	> 10 years	23, (33%)	0.561	0.025 6	(0.34, 0.93)	0.426	0.015	(0.21, 0.85)

# Discussion

In this study, the prevalence of ever tobacco use among the TRI patients was 45%. Increasing age, alcohol use, male sex, not being in a marital union were associated with higher odds of tobacco use among TRI patients, while higher level of education and longer period since diagnosis of TRI was protective.

Cancers and CVA formed the largest proportion of TRIs in this hospital-based study. This is comparable to a study on health cost of tobacco use in Uganda by Nargis et al, in which 30% of patients had CVD, 27% had oral pharyngeal cancer and 14% had COPD [39]. The settings of the studies were also similar, being national referral hospitals, but the Ugandan study was conducted in specialized units in the same center. One difference is that in our study, we reported chronic bronchitis and emphysema separately, but combined as COPD constituted the third frequently reported TRI after oral and nasopharyngeal cancer.

Nearly half of the patients in our study had history of either current or past use of tobacco. This is higher than the national average tobacco use in Kenya, pointing towards higher burden of use among patients with TRI compared with the general population [36]. Although the

epidemiological link between tobacco use and the various TRIs has strongly been demonstrated in the past, quantifying the burden in specific local contexts can provide additional impetus to tobacco control [40].

Older patients, males, those with history of alcohol use and not being in a marital union had higher odds of tobacco use in our study. Since tobacco-related morbidity and mortality manifests several decades after use initiation, burden of disease would be higher in older patients, while younger patients with TRI may have other risk factors [41]. Tobacco use prevalence is higher among males compared with females globally; therefore, burden of disease and attribution would also likely be higher among males [35]. However, this pattern may change, as more females take-up tobacco use across the world [42]. Alcohol use may be related to the same drivers of addiction as tobacco, including social, psychological, and environmental factors [43]. Marital union may represent presence of social support mechanisms, absence of which may predispose one to tobacco and other substance use [44]. A study in Ghana on tobacco use among older adults by Yawson et al showed association between tobacco use and male sex and general lack of satisfaction in life, but none with age or alcohol use; however, this study was conducted among older persons in the general population [45].

Our study has particular strengths. First, it is the first, to our knowledge, to attempt to quantify tobacco use among hospital patients with TRI in the country. Therefore, the findings will be applicable in making a public health case for sustained tobacco control. Second, the study was conducted at all national tertiary hospitals. Since, by nature most TRIs are managed at tertiary level, we are confident we captured majority of the TRIs diagnosed in the country during the period under focus. However, the study also has limitations. First, this study was hospital-based, which may not be representative of the wider population. As such the findings may not be

generalised to the country population at large. Second, the case definition for the TRI was based on the already documented diagnosis and not diagnostic investigations conducted by the study team. This could have reduced the specificity of some of the cases, especially COPD in instances where spirometry readings were unavailable. To reduce the impact of the latter on the study, every effort was made to review all supporting documentation for the diagnosis documented on the patient record. Third, tobacco use assessment was done through self-report, which could have under-estimated the prevalence due to social desirability bias.

## **Conclusion and recommendations**

Our study highlights the real-world health implications of tobacco use in Kenya. Estimating tobacco use among people diagnosed with TRI can enrich the local anti-tobacco advocacy toolkit. We recommend further studies to quantify the burden of TRIs more effectively in the population, to further inform anti-tobacco policy and practice advocacy in Kenya.

#### List of contributors

VM, SM and LO were involved in drafting the study protocol, data collection monitoring, analysis and writing of the initial draft of the manuscript. GG, AK, DK, FJ, BM, CM, KO, DM, DN, WA, RD and JO provided technical input in the development of the protocol, conduction of the study and analysis. JO provided the overall leadership in the conduction and writing of the study results. All the authors read and approved the final version of the manuscript.

#### Acknowledgements

We acknowledge the data collectors, hospital administrators, Department of non-communicable diseases, Ministry of Health, African Population and Health Research Center and Development Gateway for their facilitation in the conduction of this study.

# **Conflicts of interests**

All authors declare no conflicts of interest.

# **Funding information**

The study was funded by the Development Gateway through a grant from Bill & Melinda Gates

Foundation.

# References

- 1. Alavanja M, Baron JA, Brownson RC, Buffler PA, DeMarini DM, Djordjevic M V., et al. Tobacco Smoke and Involuntary Smoking. IARC Monogr Eval Carcinog Risks to Humans. 2004;83:1–1413.
- 2. US Centers for Disease Control and Prevention. Reducing the health consequences of smoking : 25 years of progress : a report of the Surgeon General : executive summary [Internet]. [cited 2022 Dec 31]. Available from: https://stacks.cdc.gov/view/cdc/13240.
- 3. Reitsma MB, Flor LS, Mullany EC, Gupta V, Hay SI, Gakidou E. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and initiation among young people in 204 countries and territories, 1990-2019. Lancet Public Heal. 2021;6(7):e472–81.
- 4. Bjerregaard BK, Raaschou-Nielsen O, Søresen M, Frederiksen K, Christensen J, Tjønneland A, et al. Tobacco smoke and bladder cancer--in the European Prospective Investigation into Cancer and Nutrition. Int J cancer. 2006;119(10):2412–6.
- 5. Parkin DM. 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S6.
- 6. McLaughlin JK, Hrubsec Z, Blot WJ, Fraumeni JF. Smoking and cancer mortality among U.S. veterans: A 26-year follow-up. Int J Cancer. 1995;60(2):190–3.
- 7. World Health Organization. WHO report on the global tobacco epidemic 2019: offer help to quit tobacco use [Internet]. [cited 2022 Dec 31]. Available from:

https://www.who.int/publications/i/item/9789241516204

- 8. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovi D. Low cigarette consumption and risk of coronary heart disease and stroke: Meta-analysis of 141 cohort studies in 55 study reports. Vol. 360, BMJ (Online). BMJ; 2018;
- 9. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Br Med J. 1989;298(6676):789–94.
- 10. Wilhelmsson C, Elmfeldt D, Vedin JA, Tibblin G, Wilhelmsen L. SMOKING AND MYOCARDIAL INFARCTION. Lancet. 1975;305(7904):415–20.
- 11. Critchley JA, Unal B. Health effects associated with smokeless tobacco: A systematic review. Vol. 58, Thorax. Thorax; 2003; p. 435–43.
- Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: Longitudinal population study. Br Med J. 1998;316(7137):1043–7.
- 13. Devereux G. Chronic Obstructive Pulomanry Dsiease: Definition, epidemiology, and risk factors. BMJ. 2006;332(7550):1142.
- 14. Lovasi GS, Roux AVD, Hoffman EA, Kawut SM, Jacobs DR, Barr RG. Association of environmental tobacco smoke exposure in childhood with early emphysema in adulthood among nonsmokers. Am J Epidemiol. 2010;171(1):54–62.
- Global Initiative for Chronic Obstructive Lung Disease. Archived Reports Global Initiative for Chronic Obstructive Lung Disease - GOLD [Internet]. [cited 2022 Dec 31]. Available from: https://goldcopd.org/archived-reports/.
- Pai M, Mohan A, Dheda K, Leung CC, Yew WW, Christopher DJ, et al. Lethal interaction: The colliding epidemics of tobacco and tuberculosis. Vol. 5, Expert Review of Anti-Infective Therapy. Expert Rev Anti Infect Ther; 2007; p. 385–91.
- Bhunu CP, Mushayabasa S, Tchuenche JM. A Theoretical Assessment of the Effects of Smoking on the Transmission Dynamics of Tuberculosis. Bull Math Biol. 2011;73(6):1333–57.
- Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91(1):36.
- Yen YF, Yen MY, Lin YS, Lin YP, Shih HC, Li LH, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: A population-based study. Int J Tuberc Lung Dis. 2014;18(4):492–8.
- 20. Lavigne M, Rocher I, Steensma C, Brassard P. The impact of smoking on adherence to treatment for latent tuberculosis infection. BMC Public Health. 2006;6(1):1–4.
- Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: A systematic review and meta-analysis. Vol. 4, PLoS Medicine. PLoS Med; 2007; p. 0173– 89.

- 22. Atif M, Anwar Z, Fatima RK, Malik I, Asghar S, Scahill S. Analysis of tuberculosis treatment outcomes among pulmonary tuberculosis patients in Bahawalpur, Pakistan. BMC Res Notes. 2018;11(1).
- 23. Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J. 2015;45(3):738–45.
- 24. Basu S, Stuckler D, Bitton A, Glantz SA. Projected effects of tobacco smoking on worldwide tuberculosis control: Mathematical modelling analysis. BMJ. 2011;343(7826).
- 25. Gambhir HS, Kaushik RM, Kaushik R, Sindhwani G. Tobacco smoking-associated risk for tuberculosis: A case-control study. Int Health. 2010;2(3):216–22.
- 26. Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I, Carandell E, et al. New evidence of risk factors for community-acquired pneumonia: A population-based study. Eur Respir J. 2008;31(6):1274–84.
- Nuorti JP, Cunningham SJ. Cigarette smoking and invasive pneumococcal disease. Vol. 13, Office and Emergency Pediatrics. N Engl J Med; 2000; p. 68–9.
- 28. World Health Organization. Global health risks : mortality and burden of disease attributable to selected major risks [Internet]. [cited 2022 Dec 31]. Available from: https://www.who.int/publications/i/item/9789241563871.
- 29. Reitsma MB, Kendrick PJ, Ababneh E, Abbafati C, Abbasi-Kangevari M, Abdoli A, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet (London, England). 2021;397(10292):2337.
- 30. Institute for Health Metrics and Evaluation. GBD Results [Internet]. [cited 2022 Dec 31]. Available from: https://www.healthdata.org/data-visualization/gbd-results.
- 31. World Health Organization. Global status report on noncommunicable diseases 2014 [Internet]. [cited 2022 Dec 31]. Available from: https://apps.who.int/iris/handle/10665/148114.
- Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: A systematic analysis from the global burden of disease study 2015. Lancet. 2017;389(10082):1885–906.
- 33. Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD 2019) [Internet]. [cited 2022 Dec 31]. Available from: https://www.healthdata.org/gbd/2019.
- World Health Organization. WHO global report: mortality attributable to tobacco [Internet]. [cited 2022 Dec 31]. Available from: https://www.who.int/publications/i/item/9789241564434.
- 35. World Health Organization. Tobacco: Key Facts [Internet]. [cited 2023 Jan 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco.

- Ngaruiya C, Abubakar H, Kiptui D, Kendagor A, Ntakuka MW, Nyakundi P, et al. Tobacco use and its determinants in the 2015 Kenya WHO STEPS survey. BMC Public Health. 2018;18(Suppl 3).
- 37. Gathecha G, Kiptui D, Kendagor A, Kibachio J, Amwayi S. Tobacco related morbidity among patients hospitalized at Kenyatta National Referral Hospitals Kenya. Tob Induc Dis. 2018;16(1).
- World Health Organization. Noncommunicable Disease Surveillance, Monitoring and Reporting [Internet]. [cited 2023 Apr 29]. Available from: https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps.
- 39. Nargis N, Nyamurungi K, Baine SO, Kadobera D. The health cost of tobacco use in Uganda. Health Policy Plan. 2017;32(8):1153–60.
- 40. World Health Organization. (2017). WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. World Health Organization. <u>https://apps.who.int/iris/handle/10665/255874</u>
- U.S. Department of Health and Human Services. Introduction, Evaluation of Evidence on Mechanisms of Disease Production, and Summary (How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General). Centers for Disease Control and Prevention (US); 2010; 3–12 p.
- 42. Warren CW. Differences in worldwide tobacco use by gender: Findings from the Global Youth Tobacco Survey. J Sch Health; 2003; p. 207–15.
- 43. National Institute on Alcohol Use and Alcoholism. Concurrent Alcohol and Tobacco Dependence [Internet]. [cited 2023 Jan 2]. Available from: https://pubs.niaaa.nih.gov/publications/arh26-2/136-142.htm.
- 44. Ramsey MW, Chen-Sankey JC, Reese-Smith J, Choi K. Association between marital status and cigarette smoking: Variation by race and ethnicity. Prev Med. 2019;119:48–51.
- 45. Yawson AE, Baddoo A, Hagan-Seneadza NA, Calys-Tagoe B, Hewlett S, Dako-Gyeke P, et al. Tobacco use in older adults in Ghana: Sociodemographic characteristics, health risks and subjective wellbeing. BMC Public Health. 2013;13(1):979.